Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta- Analysis

키워드

참고문헌 (40)

1. Davis KA, "Ventilator-associated pneumonia: a review", J Intensive Care Med, 21, pp.211~226 (2006)
2. Safdar N, "Clinical and economic consequences of ventilator-associated pneumonia:a systematic review", Crit Care Med, 33, pp.2184~2193 (2005)
3. Fagon JY, "Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay", Am J Med, 94, pp.281~288 (1993)
4. Craig WA, "Pharmacokinetic", pharmacodynamic parameters:rationale for antibacterial dosing of mice and men, 1998, pp.26, 1~10
5. Kim MK, "Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam", Pharmacotherapy, 22, pp.569~577 (2002)
6. Kim MK, "Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam", J Antimicrob Chemother, 48, pp.259~267 (2001)
7. Burgess DS, "Pharmacokinetics and pharmacodynamics of piperacillin", tazobactam when administered by continuous infusion and intermittent dosing, 2002, pp.24, 1090~1104
8. Roberts JA, "A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics", Crit Care Med, 37, pp.2071~2078 (2009)
9. Tamma PD, "Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials", BMC Infect Dis, 11, pp.181~ (2011)
10. Mah GT, "Evaluating outcomes associated with alternative dosing strategies for piperacillin", tazobactam: a qualitative systematic review, 2012, pp.46, 265~275
11. Deeks JJ, "Evaluating non-randomised intervention studies", Health Technol Assess, 7, pp.iii~ (2003)
12. Jadad AR, "Assessing the quality of reports of randomized clinical trials: Is blinding necessary?", Control Clin Trials, 17, pp.1~12 (1996)
13. Hanes SD, "Intermittent and continuous ceftazidime infusion for critically ill trauma patients", Am J Surg, 179, pp.436~440 (2000)
14. McNabb JJ, "Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia", Pharmacotherapy, 21, pp.549~555 (2001)
15. Georges B, "Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen", Int J Clin Pharmacol Ther, 43, pp.360~369 (2005)
16. Lorente L, "Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli", Ann Pharmacother, 40, pp.219~223 (2006)
17. Lorente L, "Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review", Clin Ther, 29, pp.2433~2439 (2007)
18. Lorente L, "Clinical cure of ventilator-associated pneumonia treated with piperacillin", tazobactam administered by continuous or intermittent infusion, 2009, pp.33, 464~468
19. Chastre J, "Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study", Crit Care Med, 36, pp.1089~1096 (2008)
20. Wang D, "Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii", Int J Antimicrob Agents, 33, pp.290~291 (2009)
21. Sakka SG, "Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial", Antimicrobial Agents Chemother, 51, pp.3304~3310 (2007)
22. Fahimi F, "Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia", Indian J Crit Care Med, 16, pp.141~147 (2012)
23. Lorente L, "Femoral venous catheterization. Does it really need to be avoided?", Med Intensiva, 33, pp.442~449 (2009)
24. Priest WS, "The effect of anticoagulants on the penicillin therapy and the pathologic lesions of subacute bacterial endocarditis", N Engl J Med, 235, pp.699~706 (1946)
25. Chant C, "Optimal dosing of antibiotics in critically ill patients by using continuous", extended infusions: a systematic review and meta-analysis, 2013, pp.17, R279~
26. Falagas ME, "Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin", tazobactam:a systematic review and meta-analysis, 2013, pp.56, 272~282
27. Teo J, "Prolonged infusion versus intermittent boluses of beta-lactam antibiotics for treatment of acute infections: a meta-analysis", Int J Antimicrob Agents, 43, pp.403~411 (2014)
28. Shiu J, "Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections", Cochrane Database Syst Rev, 3, pp.CD008481~ (2013)
29. Kasiakou SK, "Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials", Lancet Infect Dis, 5, pp.581~589 (2005)
30. Lodise TP, "Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists", Pharmacotherapy, 26, pp.1320~1332 (2006)
31. Jaruratanasirikul S, "Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection", Antimicrob Agents Chemother, 49, pp.1337~1339 (2005)
32. De Jongh R, "Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection", J Antimicrob Chemother, 61, pp.382~388 (2008)
33. Boselli E, "Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia", Intensive Care Med, 30, pp.989~991 (2004)
34. Chytra I, "Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial", Crit Care, 16, pp.R113~ (2012)
35. Roberts JA, "Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study", J Antimicrob Chemother, 59, pp.285~291 (2007)
36. Grant EM, "Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital", Pharmacotherapy, 22, pp.471~483 (2002)
37. Melsen WG, "Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies", Lancet Infect Dis, 13, pp.665~671 (2013)
38. Lodise TP Jr, "Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy", Clin Infect Dis, 44, pp.357~363 (2007)
39. Boselli E, "Alveolar concentrations of piperacillin", tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia, 2008, pp.36, 1500~1506
40. Felton TW, "Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa", Antimicrob Agents Chemother, 57, pp.5811~5819 (2013)

관련 논문AI추천